Precision BioSciences announces board member's retirement
Precision BioSciences Inc . (NASDAQ:DTIL), a profitable gene editing company with a market capitalization of $38.7 million, has announced the retirement of Dr. Sam Wadsworth from its Board of ...
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
SQZ Biotechnologies (NYSE:SQZ) vs. Precision BioSciences (NASDAQ:DTIL) Critical Contrast
SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...
Tyra Biosciences adds Adele Gulfo to board
CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment ...
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...